The estimated Net Worth of Christopher G. Chavez is at least 517$ dollars as of 21 September 2019. Christopher Chavez owns over 968 units of Endologix stock worth over 426$ and over the last 9 years Christopher sold ELGX stock worth over 91$.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Christopher Chavez ELGX stock SEC Form 4 insiders trading
Christopher has made over 3 trades of the Endologix stock since 2018, according to the Form 4 filled with the SEC. Most recently Christopher exercised 968 units of ELGX stock worth 1,481$ on 21 September 2019.
The largest trade Christopher's ever made was exercising 969 units of Endologix stock on 21 June 2019 worth over 3,488$. On average, Christopher trades about 244 units every 60 days since 2016. As of 21 September 2019 Christopher still owns at least 1,937 units of Endologix stock.
You can see the complete history of Christopher Chavez stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
What's Christopher Chavez's mailing address?
Christopher's mailing address filed with the SEC is 5830 GRANITE PKWY, STE 1100, , PLANO, TX, 75024.
Insiders trading at Endologix
Over the last 21 years, insiders at Endologix have traded over 72,068,611$ worth of Endologix stock and bought 306,824 units worth 2,023,811$ . The most active insiders traders include International, L.P. Elliott、Associates, L.P. Elliott、Capital Management Lp Camber. On average, Endologix executives and independent directors trade stock every 27 days with the average trade being worth of 13,088$. The most recent stock trade was executed by Dan Lemaitre on 4 September 2020, trading 51,844 units of ELGX stock currently worth 2,592$.
What does Endologix do?
Endologix, Inc. engages in the research, development, manufacture, and trade of medical devices for the treatment of aortic disorders such as abdominal aortic aneurysms (AAA). Its products include AFX Endovascular AAA System, Nellix and Ovation. The company was founded in March 1992 and is headquartered in Irvine, CA.
What does Endologix's logo look like?
Complete history of Christopher Chavez stock trades at Endologix
Endologix executives and stock owners
Endologix executives and other stock owners filed with the SEC include:
-
Dan Lemaitre,
Director -
Leslie V Norwalk,
Director -
David M. Jennings,
VP-Human Resources -
Iii Thomas F Zenty,
Director -
Gregory D Waller,
Director -
Michael V. Chobotov,
Chief Technology Officer -
Amanda L. De Palma,
VP, Global Marketing -
John D Mc Dermott,
Chief Executive Officer -
Christopher G. Chavez,
Director -
James Edward Machek,
VP-Research & Development -
Shari L O'quinn,
VP, Clinical & Regulatory -
Thomas Wilder,
Director -
Guido J Neels,
Director -
Jose A. Lima,
VP-Quality -
Joseph A. De John,
General Manager, Asia & Pac -
Jeremy B. Hayden,
General Counsel -
Matthew Thompson,
Chief Medical Officer -
Laura Nagel,
VP, Quality -
Stefan Schreck,
Vice President -
Vaseem Mahboob,
Chief Financial Officer -
Jeffrey F Odonnell,
Director -
Capital Management Lp Camber,
-
International, L.P. Elliott,
10% owner -
Leonard M. Greenstein,
VP Finance & Corp Controller -
Greef Roderick De,
Director -
Robert D Mitchell,
President -
Martin Tyler,
V.P. Global Marketing -
Franklin D Brown,
Executive Chairman -
Woodlands Health Ventures F...,
10% owner -
Paul Mccormick,
Chief Executive Officer & Pres -
Associates, L.P. Elliott,
10% owner -
Edward Diethrich,
Director -
Daniel Hawkins,
Vice Pres - Global Marketing -
Todd Abraham,
VP of Operations -
Janet Mary Fauls,
Vice President RA/QA/QC -
Charles Steele Love,
VP-Clinical Affairs -
Shelley B Thunen,
Chief Financial Officer -
Cecile Ferracci,
General Manager, Europe -
Ronald H Coelyn,
Director -
John Onopchenko,
CEO and Director -
Karen Uyesugi,
Vice President -
Robert John Krist,
Chief Financial Officer -
Ruth Anne Lyons,
VP Global Marketing -
Gary I. Sorsher,
Vice President - Quality -
Joseph A Bishop,
Vice President Research & Devl -
Jeffrey H Thiel,
Director -
Maurice Buchbinder,
Director -
Herbert H Mertens,
Vice President of Sales/Mktg -
Michael R Henson,
Director -
David M Richards,
Chief Financial Officer & Secr -
John Zehren,
Chief Commercial Officer -
Jeff Fecho,
Chief Quality Officer -
Jane E Kiernan,
Director -
Cynthia Buch Pinto,
Interim CFO -
Timothy Nicholas Brady,
Controller and Corp Secretary